Domov › Nemalicelični pljučni rak › Ohio › Columbus
Klinične študije za Nemalicelični pljučni rak v Columbus, OH
57 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Columbus in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Vključevanje udeležencevFaza 1/2
- The Mark H Zangmeister Center /ID# 272502, Columbus
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Health Center West, Columbus
- in še 3
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- The Ohio State University, Columbus
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- Local Institution - 0176, Columbus
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Vključevanje udeležencevFaza 3
- Ohio State University Comprehensive Cancer Center, Columbus
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Vključevanje udeležencevFaza 1
- ALX Center 10, Columbus
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Vključevanje udeležencevFaza 3
- The Ohio State University, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Vključevanje udeležencevOpazovalna študija
- The Ohio State University Comprehensive Cancer Center, Columbus
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
- OhioHealth Riverside Methodist Hospital, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Local Institution - 0102, Columbus
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Vključevanje udeležencevFaza 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Vključevanje udeležencevFaza 1
- Ohio State University, Columbus
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Vključevanje udeležencevFaza 3
- Clinical Study Sites, Columbus
- Clinical Study Site, Columbus
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Vključevanje udeležencevFaza 2/3
- Mark H. Zangmeister Cancer Center, Columbus
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Ohio State University Comprehensive Cancer Center, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Vključevanje udeležencevFaza 1/2
- Ohio State University, Columbus
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- Ohio State University, Columbus
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Ohio State University Hospital, Columbus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Ohio State University, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Vključevanje udeležencevFaza 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Vključevanje udeležencevFaza 3
- Ohio State University Hospitals, Columbus
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Vključevanje udeležencevOpazovalna študija
- Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Vključevanje udeležencevFaza 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Vključevanje udeležencevFaza 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Ohio State University, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Ohio State University, Columbus
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Vključevanje udeležencevFaza 1/2
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Vključevanje udeležencevFaza 1
- Local Institution - 0045, Columbus
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Ohio State University Comprehensive Cancer Center, Columbus
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Ohio State University Comprehensive Cancer Center, Columbus
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
Vključevanje udeležencevFaza 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Vključevanje udeležencev
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Vključevanje udeležencevFaza 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Ohio State University, Columbus
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · 7 mi stran
- in še 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Vključevanje udeležencevFaza 1/2
- The Ohio State University Wexner Medical Center, Columbus
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- in še 7
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Vključevanje udeležencevFaza 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Vključevanje udeležencevFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- Memorial Hospital, Marysville · 27 mi stran
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Ohio State University Comprehensive Cancer Center, Columbus
GEMINI-NSCLC: NSCLC Biomarker Study
Vključevanje udeležencevOpazovalna študija
- Ohio State University, Columbus
- OhioHealth Reseach Institute, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Vključevanje udeležencevFaza 1/2
- The Ohio State University, Columbus
Študije za Nemalicelični pljučni rak v drugih mestih
- Houston, TX145 študij
- New York City, NY121 študij
- Arlington, VA104 študij
- Nashville, TN97 študij
- Boston, MA90 študij
- Los Angeles, CA87 študij
- St. Louis, MO73 študij
- Chicago, IL61 študij
- Baltimore, MD60 študij
- San Antonio, TX59 študij
- Washington, DC55 študij
- Seattle, WA53 študij
Druge študije v Columbus
- Rak dojke40 študij
- Rak jajčnikov39 študij
- Rak (vse vrste)38 študij
- Rak pljuč37 študij
- Akutna mieločna levkemija35 študij
- Kronična limfocitna levkemija28 študij
- Metastatski rak27 študij
- Rak endometrija25 študij
- Rak prostate24 študij
- Množni mielom24 študij
- Kolorektalni rak24 študij
- Melanom21 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.